| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 18, 2025Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/...
Nov 19, 2024Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and...
Aug 20, 2024Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain...
May 23, 2024Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product...
Feb 20, 2024Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S....
Feb 21, 2023Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios DUBLIN, Feb. 21, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced...
-
Mar 24, 2022
TITAN 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy DUBLIN, March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE:...
-
Feb 22, 2022- New InterStim X™ system provides 10 to 15 years of battery life without the need to recharge
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation...
-
Feb 22, 2022
Company advanced its pipeline, launched new products, won share, and delivered earnings growth despite COVID-19 impact on healthcare procedure volumes DUBLIN, Feb. 22, 2022 /PRNewswire/ --...
Nov 23, 2021Company continued to launch new products, win share, and deliver strong earnings growth; market procedure volumes impacted by COVID-19 resurgenceMedtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021. Key Highlights Revenue of $7.8 billion increased 3% reported...
-
Sep 22, 2021Medtronic Will Move to Request Litigation Proceedings Resume
Medtronic (NYSE:MDT), the global leader in medical technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed an additional...
-
Sep 13, 2021Medtronic Receives Affirmation of Three Additional Sacral Neuromodulation Patents
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its intellectual property (IP) for its sacral...
Aug 24, 2021Strong Financial Performance on Continued Procedure Volume Recovery and Share Gains from New Product LaunchesMedtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021. Key Highlights Revenue of $8.0 Billion Increased 23% Reported and...
-
May 27, 2021- Q4 Revenue of $8.2 Billion Increased 37% Reported and 32% Organic
Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2021, which ended April 30, 2021. The company reported fourth quarter worldwide revenue of $8.188...
-
Apr 27, 2021New Investigational Device Aims to Expand Access to Therapy for Patients with Incontinence; Underscores Medtronic's Leadership as Only Company to Offer Neuromodulation Options for Incontinence
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced approval from the U.S. Food and Drug Administration (FDA) to proceed with an investigational device exemption...
-
Feb 18, 2021
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for expanded MRI labeling of...
-
Oct 14, 2020
Company Raises Revenue Growth Outlook Highlights Deep and Broad Pipeline and Technology Platforms DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical...
-
Oct 6, 2020ELITE is the Only Study of a Rechargeable Sacral Neurostimulation System to Include All Four Indications, Including Fecal Incontinence, Which Affects Millions
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first patient was implanted in its ELITE study of the InterStim™ Micro system — the only study of a...
-
Sep 25, 2020U.S. Patent and Trademark Office Rejects IPR Challenge to Medtronic Patent
Medtronic (NYSE:MDT) has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStim™ systems. The Patent Trial and Appeal...
-
Aug 20, 2020ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and Non-Obstructive Urinary Retention
DUBLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has begun recruitment of the prospective, multicenter, global,...
-
Aug 5, 2020First Patient Receives New Sacral Neuromodulation Device Implant at Cleveland Clinic
DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for...
-
Aug 3, 2020World’s Smallest Rechargeable Bladder/Bowel Control System — InterStim Micro — Features Trusted MRI Technology for Full-Body 1.5 and 3 Tesla MRI Scans
DUBLIN, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug...
-
Jan 13, 2020Full-Body MRI-Conditional InterStim II and InterStim Micro Systems Offer Lifestyle-Friendly Choices in Sacral Neuromodulation Therapy to Europeans Suffering from Incontinence
DUBLIN, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received CE Mark for its InterStim™ Micro neurostimulator and InterStim™ SureScan™ MRI leads —...
-
Nov 19, 2019Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic
DUBLIN, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2020, which ended October 25, 2019. The company reported...
-
Nov 4, 2019Action Seeks Relief to Prevent Further Infringement of Medtronic Patents
DUBLIN, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Medtronic, Inc. (NYSE:MDT) today filed a lawsuit against Axonics Modulation Technologies, Inc. (“Axonics”) alleging infringement of patents related to...
-
Oct 7, 2019Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with Bladder and Bowel Control Issues
DUBLIN, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has filed a pre-market approval (PMA) supplement with the United States Food and Drug Administration (FDA) for...
-
Aug 20, 2019Revenue of $7.5 Billion Increased 1.5% Reported; Increased 3.5% Constant Currency
DUBLIN, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2020, which ended July 26, 2019. The company reported...
-
Dec 17, 2018Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence
DUBLIN - December 17, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the InterStim(TM) smart programmer for use with the InterStim system,...
-
Nov 20, 2018Revenue of $7.5 Billion Increased 6.1% Reported; Increased 7.5% Organic
DUBLIN - November 20, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2019, which ended October 26, 2018. The company reported second...
-
Nov 21, 2017Revenue of $7.1 Billion; GAAP Diluted EPS of $1.48; Non-GAAP Diluted EPS of $1.07
DUBLIN - November 21, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2018, which ended October 27, 2017. The company reported second...
-
Jul 17, 2017The InterStim System is the Only Proven, Long-Term Sacral Neuromodulation Solution for Overactive Active Bladder
DUBLIN - July 17, 2017 - Medtronic plc (NYSE: MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of...
-
Mar 30, 2016New Medtronic Treatment Targets Underlying Bladder and Brain Miscommunication and Could Bring Desperately Needed Relief to Tens of Millions Struggling with OAB
DUBLIN - March 30, 2016 - Medtronic plc (NYSE: MDT) today announced the launch of its NURO(TM) System that delivers percutaneous tibial neuromodulation (PTNM) for the treatment of overactive...
-
Nov 18, 2014Revenue of $4.4 Billion Grew 5% on Constant Currency Basis; 4% as Reported
MINNEAPOLIS - Nov. 18, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2015, which ended October 24, 2014. The company reported worldwide...
-
Oct 7, 2014FDA-Approved System Provides Patients with Added Benefits While Testing Innovative Therapy for Bladder and Bowel Incontinence
MINNEAPOLIS - October 7, 2014 - After living with overactive bladder and urinary retention symptoms for 11 years, Jennifer LaForest, a 26-year-old woman from Auburn Hills, Michigan, recently...
-
Aug 19, 2014Revenue of $4.3 Billion Grew 4% on Constant Currency Basis; 5% as Reported
MINNEAPOLIS - Aug. 19, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2015, which ended July 25, 2014. The company reported worldwide...
-
Aug 20, 2013Revenue of $4.1 Billion Grew 3% at Constant Currency; 2% as Reported
MINNEAPOLIS - August 20, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2014, which ended July 26, 2013. The company reported worldwide...
-
May 21, 2013Q4 Revenue of $4.5 Billion Grew 5% at Constant Currency; 4% as Reported
MINNEAPOLIS - May 21, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2013, which ended April 26, 2013. The Company reported worldwide...
-
Feb 19, 2013Revenue of $4.0 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS - February 19, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2013, which ended January 25, 2013. The Company reported...
-
Nov 20, 2012Revenue of $4.1 Billion Grew 5% on a Constant Currency Basis; 2% as Reported
MINNEAPOLIS - November 20, 2012 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2013, which ended October 26, 2012. The Company reported...
-
Aug 21, 2012Revenue of $4.0 Billion Grew 5% on a Constant Currency Basis; 2% as Reported
MINNEAPOLIS - August 21, 2012 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2013, which ended July 27, 2012. The Company reported worldwide...
-
May 22, 2012Revenue of $4.3 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--May. 22, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 27, 2012. The company reported...
-
Feb 21, 2012Revenue of $3.9 Billion Driven by International Revenue Growth of 6% on a Constant Currency Basis, 7% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 21, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2012, which ended January 27, 2012. The company...
-
Nov 20, 2011Revenue of $4.1 Billion Grew 3% on a Constant Currency Basis, 6% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 22, 2011-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2012, which ended October 28, 2011. The company...
-
Aug 23, 2011Revenue of $4 Billion Driven by International Growth of 7% on a Constant Currency Basis; 19% as Reported
MINNEAPOLIS, Aug 23, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2012, which ended July 29, 2011. The Company...
-
Aug 15, 2011InterStim Therapy for Bowel Control Recently Approved by the U.S. FDA
MINNEAPOLIS, Aug 15, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using...
-
May 24, 2011Record Fourth Quarter Revenue of $4.3 Billion Driven by Strong International Growth of 12%
MINNEAPOLIS, May 24, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 29, 2011. Medtronic recorded fiscal...
-
Apr 1, 2011Unique Sacral Nerve Stimulation Therapy Now Available for Treatment of Chronic Fecal Incontinence
MINNEAPOLIS, Apr 01, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of InterStim(R) Therapy for Bowel Control. InterStim...
-
Feb 20, 2011Revenue of $4.0 Billion Grew 3% on Strength of New Products
MINNEAPOLIS, Feb 22, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2011, which ended January 28, 2011. The company...
-
Nov 29, 2010International Revenue of $1.6 Billion Grew 6% on a Constant Currency Basis; 4% As Reported
MINNEAPOLIS, Nov 23, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2011, which ended October 29, 2010. The company...
-
Nov 1, 2010
MINNEAPOLIS, Nov 18, 2010 (BUSINESS WIRE) -- Medtronic Inc. (NYSE: MDT), the leader in spinal cord stimulation for more than 25 years, today announced U.S. Food and Drug Administration (FDA)...